New Study Validates GENinCode's CARDIO InCode-Score For Predicting CHD Risk

In a significant stride towards the prevention of cardiovascular disease, GENinCode Plc, a company dedicated to the advancement of polygenics, has announced the publication of a pivotal study in the American Journal of Preventive Cardiology. This research, focusing on 'Polygenic Risk and Incident Heart Disease in a large multiethnic cohort', sheds light on the potential of polygenic risk scores in identifying individuals at high risk of Coronary Heart Disease (CHD).

The study was conducted by the Kaiser Permanente Division of Research and delved into the health data of over 63,000 adults. These individuals, part of the Kaiser Permanente Northern California Genetic Epidemiology Resource in Adult Health and Aging (GERA) cohort, had no prior history of CHD. Over an average follow-up period of 14 years, researchers utilized the CARDIO inCode-Score® to evaluate the polygenic risk and subsequent CHD incidence among this diverse group.

Findings from this extensive study indicate that the CARDIO inCode-Score® is effective in pinpointing individuals at the highest risk for CHD. Such individuals could greatly benefit from early lifestyle modifications and, where necessary, therapeutic interventions. Notably, previous analyses involving the CARDIO inCode-Score® revealed that individuals with a high genetic predisposition to CHD could reduce their risk by 52% through adopting a favorable lifestyle compared to those with an unfavorable one.

This research underscores the importance of integrating polygenic risk scores with traditional clinical assessments to enhance preventive care strategies. By doing so, healthcare providers can more accurately identify those who would benefit most from early intervention. Polygenic risk assessment holds particular promise for younger populations before the onset of conventional risk factors like high blood pressure or diabetes.

GENinCode is at the forefront of commercializing its CARDIO inCode-Score®, partnering with leading healthcare institutions to offer a more precise estimation of an individual's lifetime risk of heart attack. The company's state-of-the-art CLIA and CAP accredited labs in Irvine, California are set to deliver CIC-Score assessments. Furthermore, GENinCode has recently submitted its CIC-Score 'De Novo' medical device for FDA approval, marking a crucial step towards broader adoption.

In addition to its research endeavors, GENinCode will be participating in the Annual ACC Meeting from April 6-8 in Atlanta. This event presents an opportunity for further engagement and discussion on the advancements in cardiovascular disease prevention.

The integration of polygenic risk scores into clinical practice represents a promising avenue for reducing the incidence of CHD through personalized preventive care. As GENinCode continues its efforts to gain FDA approval for its innovative medical device, the potential for significant impact on public health remains high.